♜ Fallacy 3: Impact of JCA is limited to Europe – really?♜

 

🌍 JCA is an assessment of clinical evidence on behalf of all 27 member states of the European Union, and 3 EEA countries. All member states need to take the JCA report into account. It is mandated by HTAR (Health Technology Assessment Regulation), so European law.

 

🤔 Fair to expect that impact will be limited to Europe.

 

⚖️ On the other hand, the JCA dossier will be an information repository of unmatched details and number of comparisons. And published by leading European HTA agencies. Both, the JCA as well as the JCA report, are publicly available and written in English. It is hard to believe that payers outside Europe will not notice and take this into account as well. This is similar to NICE appraisals, just to give one example.

 

If this is true, this spillover will change the nature and governance of JCA projects:

🔹 Including the global organization in key decisions around JCA,

🔹 informing them on the AssessmentScope,

🔹 sharing the draft JCA report,

🔹 and preparing for Q and A to handle upcoming discussions with payers outside Europe.